Literature DB >> 23954730

Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3β signaling pathway.

Juliana B Hoppe1, Karine Coradini, Rudimar L Frozza, Claudia M Oliveira, André B Meneghetti, Andressa Bernardi, Elisa Simões Pires, Ruy C R Beck, Christianne G Salbego.   

Abstract

Alzheimer's disease (AD), a neurodegenerative disorder exhibiting progressive loss of memory and cognitive functions, is characterized by the presence of neuritic plaques composed of neurofibrillary tangles and β-amyloid (Aβ) peptide. Drug delivery to the brain still remains highly challenging for the treatment of AD. Several studies have been shown that curcumin is associated with anti-amyloidogenic properties, but therapeutic application of its beneficial effects is limited. Here we investigated possible mechanisms involved in curcumin protection against Aβ(1-42)-induced cognitive impairment and, due to its poor bioavailability, we developed curcumin-loaded lipid-core nanocapsules in an attempt to improve the neuroprotective effect of this polyphenol. Animals received a single intracerebroventricular injection of Aβ(1-42) and they were administered either free curcumin or curcumin-loaded lipid-core nanocapsules (Cur-LNC) intraperitoneally for 10days. Aβ(1-42)-infused animals showed a significant impairment on learning-memory ability, which was paralleled by a significant decrease in hippocampal synaptophysin levels. Furthermore, animals exhibited activated astrocytes and microglial cells, as well as disturbance in BDNF expression and Akt/GSK-3β signaling pathway, beyond tau hyperphosphorylation. Our findings demonstrate that administration of curcumin was effective in preventing behavioral impairments, neuroinflammation, tau hyperphosphorylation as well as cell signaling disturbances triggered by Aβ in vivo. Of high interest, Cur-LNC in a dose 20-fold lower presented similar neuroprotective results compared to the effective dose of free curcumin. Considered overall, the data suggest that curcumin is a potential therapeutic agent for neurocognition and nanoencapsulation of curcumin in LNC might constitute a promising therapeutic alternative in the treatment of neurodegenerative diseases such as AD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt/GSK-3β pathway; Alzheimer’s disease; BDNF; Curcumin; Hippocampus; Lipid-core nanocapsules; β-Amyloid

Mesh:

Substances:

Year:  2013        PMID: 23954730     DOI: 10.1016/j.nlm.2013.08.001

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  43 in total

1.  Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice.

Authors:  Ge Jin; Lin Zhu; Peng Liu; Qian Xu; Yue Qi; Xiaoyu Zhou; Jikai Xu; Xuefei Ji; Tianyan Chi; Libo Zou
Journal:  J Physiol Sci       Date:  2019-02-14       Impact factor: 2.781

Review 2.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

Review 3.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

4.  Lipopolysaccharide and Curcumin Co-Stimulation Potentiates Olfactory Ensheathing Cell Phagocytosis Via Enhancing Their Activation.

Authors:  Ding-Jun Hao; Cuicui Liu; Lingling Zhang; Bo Chen; Qian Zhang; Rui Zhang; Jing An; Jingjing Zhao; Mingmei Wu; Yi Wang; Alfred Simental; Baorong He; Hao Yang
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 5.  Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.

Authors:  Sophie West; Praveen Bhugra
Journal:  Br J Clin Pharmacol       Date:  2015-06-08       Impact factor: 4.335

6.  Sevoflurane attenuates stress-enhanced fear learning by regulating hippocampal BDNF expression and Akt/GSK-3β signaling pathway in a rat model of post-traumatic stress disorder.

Authors:  Chunlong Chen; Muhuo Ji; Qian Xu; Yao Zhang; Qian Sun; Jian Liu; Sihai Zhu; Weiyan Li
Journal:  J Anesth       Date:  2014-12-23       Impact factor: 2.078

7.  Dexmedetomidine mitigates sevoflurane-induced cell cycle arrest in hippocampus.

Authors:  Li-Jun Bo; Pei-Xia Yu; Fu-Zhen Zhang; Zhen-Ming Dong
Journal:  J Anesth       Date:  2018-08-20       Impact factor: 2.078

8.  In Vitro Modulation of TrkB Receptor Signaling upon Sequential Delivery of Curcumin-DHA Loaded Carriers Towards Promoting Neuronal Survival.

Authors:  Luis P B Guerzoni; Valérie Nicolas; Angelina Angelova
Journal:  Pharm Res       Date:  2016-12-19       Impact factor: 4.200

9.  Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, Mechanisms, and Therapy.

Authors:  Jing-Hui Song; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-10-30       Impact factor: 5.590

10.  Nerolidol-loaded nanospheres prevent behavioral impairment via ameliorating Na+, K+-ATPase and AChE activities as well as reducing oxidative stress in the brain of Trypanosoma evansi-infected mice.

Authors:  Matheus D Baldissera; Carine F Souza; Thirssa H Grando; Karen L S Moreira; Andressa S Schafer; Luciana F Cossetin; Ana P T da Silva; Marcelo L da Veiga; Maria Izabel U M da Rocha; Lenita M Stefani; Aleksandro S da Silva; Silvia G Monteiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.